Mesoblast Ltd ADR(MESO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 6:58 AM ET (Korea 10/27 19:58)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.45 | Insider Own | - | Shs Outstand | 130.1M | Perf Week | 3.68% |
| Market Cap | 1.61B | Forward P/E | 93.71 | EPS next Y | 180.55% | Insider Trans | - | Shs Float | 128.3M | Perf Month | -18.06% |
| Enterprise Value | 1.64B | PEG | - | EPS next Q | -0.08 | Inst Own | 3.01% | Short Float | 2.58% | Perf Quarter | -14.26% |
| Income | -0.06B | P/S | 13.37 | EPS this Y | 63.03% | Inst Trans | -35.14% | Short Ratio | 14.5 | Perf Half Y | -19.18% |
| Sales | 0.12B | P/B | 2.83 | EPS next 5Y | - | ROA | -7.4% | Short Interest | 3.30M | Perf YTD | -31.32% |
| Book/sh | 4.38 | P/C | 15.66 | EPS past 3/5Y | 24.72% 22.09% | ROE | -9.89% | 52W High | -42.37% ($21.50) | Perf Year | -26.29% |
| Cash/sh | 0.79 | P/FCF | - | Sales past 3/5Y | 152.9% 74.52% | ROIC | -8.45% | 52W Low | 4.21% ($11.89) | Perf 3Y | 429.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 47.33% | Gross Margin | 84.1% | Volatility(W/M) | 2.69% 2.85% | Perf 5Y | -0.72% |
| Dividend TTM | - | EV/Sales | 13.57 | Sales Y/Y TTM | 600.89% | Oper. Margin | -42.63% | ATR (14) | 0.54 | Perf 10Y | 52.41% |
| Dividend Ex-Date | - | Quick Ratio | 2.09 | EPS Q/Q | 12.33% | Profit Margin | -47.8% | RSI (14) | 35.89 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.43 | Sales Q/Q | -5.36% | SMA20 | -8.67% ($13.57) | Beta | 2.24 | Target Price | $30.37 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/8/26 | SMA50 | -18.2% ($15.15) | Rel Volume | 0.47 | Prev Close | $12.28 |
| Employees | 108 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | -23.98% -6.61% | SMA200 | -20.06% ($15.5) | Avg Volume(3M) | 0.23M | Price | $12.39 |
| IPO | 2006/1/18 | Option/Short | Yes/Yes | Trades | 1345 | Volume | 107,364 | Change | 0.9% |
🧬 A biotech company that develops and commercializes allogeneic cell therapies. Leveraging a stem cell-based allogeneic cell therapy platform, it develops treatments targeting graft-versus-host disease as well as cardiovascular and spinal conditions, and maintains both commercialized products and a clinical pipeline. The company has established itself as a cell therapy biotech player with an allogeneic cell therapy platform and a differentiated approach to regenerative medicine.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
MESO has a sound balance sheet but weak earning power
Of every $100 in sales, $42.63 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +63.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,337. Peers typically go for $1,213.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -0.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #114 of 594 in the industry
Based on market cap of $2B.
ABSI#113 Absci Corp $2B PER - MESO#114 Mesoblast Ltd ADR $2B PER - 
IMCR#115 Immunocore Holdings plc ADR $2B PER - 
NBTX#116 Nanobiotix ADR $2B PER - 
NUVB#117 Nuvation Bio Inc $2B PER - 
FAQ
What kind of company is MESO?
MESO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MESO?
The market cap of MESO is approximately $1.6B, ranking 2,218 within its sector.
What is the 52-week high and low for MESO?
MESO has recorded a 52-week high of $21.50 and a low of $11.89.
